REGENXBIO financials
$7.45−0.27%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $170.4M | $83.3M | $90.2M | $112.7M | $470.3M | $154.6M | $35.2M | $218.5M | $10.4M | $4.6M |
| Gross profit | $150.1M | $49.8M | $53.0M | $58.2M | $418.5M | $118.9M | $27.0M | $208.9M | $8.7M | $3.6M |
| Gross margin | 88.1% | 59.7% | 58.8% | 51.6% | 89.0% | 76.9% | 76.6% | 95.6% | 83.6% | 79.1% |
| Operating income | -$161.2M | -$233.3M | -$268.1M | -$262.9M | $160.0M | -$119.2M | -$149.0M | $88.1M | -$75.9M | -$65.3M |
| Net income | -$193.9M | -$227.1M | -$263.5M | -$280.3M | $127.8M | -$111.3M | -$94.7M | $99.9M | -$73.2M | -$63.0M |
| Net margin | −113.8% | −272.5% | −292.0% | −248.7% | 27.2% | −72.0% | −268.9% | 45.7% | −704.0% | −1372.1% |
| Diluted EPS | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $2.91 | $-2.98 | $-2.58 | $2.73 | $-2.45 | $-2.38 |
| EBITDA | -$145.6M | -$215.0M | -$250.8M | -$250.0M | $167.0M | -$103.1M | -$141.8M | $92.1M | -$73.2M | -$64.8M |
| Operating cash flow | -$124.0M | -$173.1M | -$218.4M | -$207.5M | $218.9M | -$54.1M | -$107.7M | $104.6M | -$58.0M | -$48.6M |
| Free cash flow | -$126.4M | -$175.6M | -$228.4M | -$238.2M | $134.7M | -$80.9M | -$119.4M | $91.4M | -$65.2M | -$56.7M |
| Diluted shares | 51.6M | 49.5M | 43.7M | 43.2M | 43.9M | 37.3M | 36.7M | 36.6M | 29.9M | 26.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $34.5M | $57.5M | $34.5M | $97.0M | $345.2M | $338.4M |
| Short-term investments | $195.6M | $177.2M | $240.7M | $267.7M | $112.2M | $137.3M |
| Total debt | $0.00 | $0.00 | $43.5M | $0.00 | $0.00 | $0.00 |
| Total assets | $453.0M | $466.0M | $574.0M | $833.3M | $1.11B | $708.2M |
| Total liabilities | $350.3M | $206.3M | $262.2M | $317.1M | $349.6M | $330.4M |
| Shareholders' equity | $102.7M | $259.7M | $311.7M | $516.2M | $764.3M | $377.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology